# Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)

> **NCT04530604** · PHASE1 · COMPLETED · sponsor: **Gregory Yanik** · enrollment: 13 (actual)

## Conditions studied

- COVID
- Sars-CoV2
- COVID-19
- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** Defibrotide

## Key facts

- **NCT ID:** NCT04530604
- **Lead sponsor:** Gregory Yanik
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2021-03-26
- **Final completion:** 2021-04-09
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04530604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04530604, "Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04530604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*